| 描述信息 |
Non-invasive liquid biopsy is a promising strategy for ovarian cancer (OC) detection. We evaluated the feasibility and efficacy of a multi-analyte approach combining circulating tumor DNA (ctDNA) detection with protein biomarkers for early OC detection. At 95% specificity, predictive models using CA125 and ctDNA alone exhibited an overall sensitivity of 79.0% and 58.7%, respectively; however, when CA125 was combined with ctDNA, sensitivity reached 85.5%. Integrating CA125 and human epididymis protein-4 (HE4) in the Risk of Ovarian Malignancy Algorithm (ROMA) index, yielded a sensitivity of 86.2%. When four additional proteins were added to CA125 and ctDNA in the EarlySEEK model, sensitivity increased to 94.2%. In patients with early-stage epithelial OC, CA125 alone yielded a sensitivity of 63.5%, whereas the sensitivities of the CA125+ctDNA, ROMA, and EarlySEEK models were 73.1%, 76.9%, and 90.4%, respectively. EarlySEEK was not affected by menopausal status, and outperformed CA125 and ROMA in distinguishing benign and malignant ovarian tumors in post-menopausal populations. Thus, EarlySEEK could be employed for early OC detection. |
